David Altshuler is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. Dr. Altshuler leads Vertex’s research efforts aimed at discovering new medicines for the treatment of CF and other serious diseases, overseeing the company’s three research sites in Boston, San Diego and Oxford, UK.

David was previously one of four founding members, Deputy Director and Chief Academic Officer at the Broad Institute of Harvard and MIT, a professor at Harvard and MIT, and a physician at Massachusetts General Hospital. He was a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and discovered over 100 gene variants associated with type 2 diabetes and other common diseases.

David serves as Chair of the Wellcome Trust Sanger Institute’s Scientific Advisory Board. A member of the National Academy of Medicine and the American Academy of Arts and Sciences, David was named a Champion of Change by the White House for his leadership in creating and leading the Global Alliance for Genomic and Health.

Pharmaceutical Genetics, Physician, Health, Healthcare,